ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Key Takeaways

  • Masks and other rose $50.37 M, while devices added $39.98 M over the year.
  • Devices still take 57% of Sleep and Breathing Health sales, but masks are catching up.
  • Masks and other rose to 38% of total sales this quarter, from 37% a year earlier.
  • Residential Care Software fell $11.12 M, the only piece shrinking as total sales grew 5.9%.
  • Devices alone brought in $720.29 M, which is 51% of all sales, so one product line carries the business.

The Unvarnished Truth

Masks and other grew 10%, outpacing devices at 6%.

Masks and other rose $50.37 M this quarter, to $539.51 M, against $489.14 M a year earlier; devices rose $39.98 M, to $720.29 M. The masks line grew faster, and it is now 43% of Sleep and Breathing Health sales, up from 42% a year earlier. Residential Care Software fell $11.12 M in the same period, so sleep products carried the total, which grew 5.9%. The MD&A says the planned discontinuation of the Astral device cut life support device sales, partially offsetting growth.

Why did masks outrun devices? The MD&A gives one shared cause for both lines: the increase in net revenue on devices and masks was primarily attributable to increased demand and unit sales across the sleep health portfolio. It does not split masks from devices, so the faster masks line goes unexplained. The filing does give regional detail: Rest of World masks grew 12%, against 10% in the Americas, and currency explains part of that gap, since at constant currency Rest of World masks grew 11%.

Put together, the growth is shifting toward masks and other, and devices, the bigger line, are growing more slowly. Devices still carry the larger dollar base, $720.29 M against $539.51 M. The gap matters because it changes which product line the company leans on as it grows, and the filing does not say which way that goes. Will masks and other keep outgrowing devices once the Astral exit is out of the base, or was this quarter's gap a one-off?

Revenue by Business Segment by Subsegment

Swipe to see the full flow
ResMed Inc. (RMD) FY2027 Q1 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETSleep and Breathing Health - DevicesSleep and Breathing Health - Masks and otherResidential Care SoftwareNet revenueGross profitCost of salesIncome from operationsTotal operating expensesTotal operating expensesTotal other income (loss), netIncome before income taxesNet incomeIncome taxesTotal other income (loss), netTotal other income(loss), net$86.17 MIncome before income taxesPretax income$539.16 MNet revenueNet revenue$1.41 BGross profitGross profit$870.57 MIncome from operationsIncome from operations$452.98 MNet incomeNet income$418.41 MSleep and Breathing Health - DevicesSleep and Breathing Health - Devices$720.29 MTotal operating expensesTotal operatingexpenses$417.58 MIncome taxesIncome taxes$120.74 MTotal operating expensesTotal operating expenses$417.58 MSleep and Breathing Health - Masks and otherSleep and BreathingHealth - Masks and other$539.51 MCost of salesCost of sales$544.25 MResidential Care SoftwareResidential Care Software$155.01 M
Chart details

ResMed Inc. (RMD) FY2027 Q1 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
1,414,814,000 US dollars
Cost of sales
544,247,000 US dollars
Gross profit
870,567,000 US dollars
Total operating expenses
417,583,000 US dollars
Income from operations
452,984,000 US dollars
Total other income (loss), net
86,171,000 US dollars
Income before income taxes
539,155,000 US dollars
Income taxes
120,742,000 US dollars
Net income
418,413,000 US dollars
Residential Care Software
155,012,000 US dollars
Sleep and Breathing Health - Devices
720,292,000 US dollars
Sleep and Breathing Health - Masks and other
539,510,000 US dollars
Total operating expenses
417,583,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
ResMed Inc. (RMD) FY2027 Q1 Revenue by Business Segment by Subsegment Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Intelligent Insights for Investors

What is inside the biggest piece of ResMed's sales?

Sleep and Breathing Health is the biggest piece: its products brought in 89% of sales this quarter, and Devices made up 57% of them. Masks and other made up the other 43%.

What drove the change in ResMed's biggest business over the past year?

Mostly Masks and other: it added $50.37 M of the $90.36 M rise in revenue from Sleep and Breathing Health over the year. That is 56% of the group's growth.

Intelligent Insights for Lenders

How much does ResMed depend on its biggest piece of sales?

Heavily: Sleep and Breathing Health - Devices brought in 51% of total sales this quarter, against 38% for Masks and other, the next largest.

Intelligent Insights for Employees

Which part of sales by product grew fastest over the past year?

Masks and other grew fastest: up 10% this quarter, against 6% for devices.

Intelligent Insights for Suppliers

Does one product line dominate ResMed's largest business?

Yes: Devices made up 57% of the Sleep and Breathing Health products ResMed lists this quarter, against 43% for Masks and other.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!